Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab | BMJ Case Reports

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Global health

Authors

About

Help
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Unexpected outcome (positive or negative) including adverse drug reactions

CASE REPORT

Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Rickard F, Hyams C, Low AT

Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab

Case Reports 2018;2018:bcr-2018-224485.